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nnumerable reviews on addictive disorders
have been written by many groups,including our own,
over the past decade.
1-17 We have contributed over 20
reviews,commentaries,perspectives,or viewpoints in the
last 5 years. In 2004, my laboratory published a review
article on “Evolving perspectives in neurobiological
research in the addictions.”
18Therefore,for this state-of-
the-art review with conceptual insights, focus will be
placed on research conducted in our Laboratory and
Center over the last 5 years.For further information and
for some relevant citations of other research groups,one
can consult some reviews which we have prepared on
basic molecular neurobiology, with a focus on cocaine
and other stimulant addictions, opiate addiction, and
alcoholism.
1-6We have published other reviews and per-
spectives on research related to stress responsivity,and
also genetics related to stress responsivity, and with
emphasis on the role of stress responsivity.
5,7,8,11 Further,
and relatively exhaustive,reviews on human molecular
genetics related to the addictions may be found in yet
other recent publications from our laboratory.
9,10 Finally,
reviews of the history of treatment research in our own
laboratory,as well as overviews of recent contributions
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The articulated goals of Dialogues in Clinical Neuroscience
are to serve as “an interface between clinical neuropsy-
chiatry and the neurosciences by providing state-of-the-
art information and original insights into relevant clinical,
biological, and therapeutic aspects.” My laboratory, the
Laboratory of the Biology of Addictive Diseases at The
Rockefeller University, has for years been focused on “bidi-
rectional translational research,” that is, learning by care-
ful observations and study in patient populations with the
disorders under study, in this case primarily specific addic-
tive diseases, and then using that knowledge to create
improved animal models or other laboratory-based
research paradigms, while, at the same time, taking
research findings made at the bench into the clinic as
promptly as that is appropriate and feasible. In this invited
review, therefore, the focus will be on perspectives of our
Laboratory of the Biology of Addictive Diseases and
related National Institutes of Health/National Institute on
Drug Abuse research Center, including laboratory-based
molecular neurobiological research, research using several
animal models designed to mimic human patterns of drug
abuse and addiction, as well as basic clinical research,
intertwined with treatment-related research. 
© 2007, LLS SAS Dialogues Clin Neurosci. 2007;9:363-378.This review will be presented in three sections:(i) labo-
ratory-based molecular neurobiological and neuro-
chemical studies related to cocaine and opiate addiction
and potential new approaches to treatment thereof;(ii)
role of stress responsivity in the acquisition and persis-
tence of specific addictive diseases, and the impact of
chronic exposure to drugs of abuse and withdrawal there-
from on components of the stress-responsive system,
along with identification of potential new targets for ther-
apeutic intervention; and (iii) basic clinical research
related to specific addictive diseases,with emphasis on
stress responsivity: all research focused on treatment
improvement.
Laboratory-based molecular neurobiological
and neurochemical studies related to cocaine
and opiate addiction, and potential new
approaches to treatment thereof
Over the past several years,we have developed several
animal models for acute,subacute,and chronic exposure
to specific drugs of abuse,with emphasis on cocaine,mor-
phine and heroin, and alcohol. One of these models,
which we have developed, validated, and used exten-
sively in our studies,is “binge”-pattern cocaine admin-
istration mimicking the most common pattern of human
abuse.In studies from our laboratory in which animals
were allowed to self-administer cocaine with presenta-
tion of high,as well as moderate,and the usual low doses
of cocaine,and with extended access (10 hours) provided,
we found that animals will escalate their use of cocaine.
19
In fact, by 5 days of extended access to high doses of
cocaine rats will self-administer more than twice the dose
which we had usually used in our chronic “binge-pattern”
cocaine administration (15 mg/kg x3, that is 45
mg/kg/day).We have extended this “binge-pattern,”using
both the steady-dose and escalating-dose “binge-pattern”
administration of cocaine.
19We have been able to study
various behavioral factors, as well as impact on gene
expression,comparing these two models.
One of the most important early findings from our labo-
ratory (and others) on gene expression has been the find-
ing of significant increased preprodynorphin gene
expression in the striatum of rodents after acute,suba-
cute,and chronic cocaine administration (eg,refs 20,21).
This is especially important since we and others have
shown that dynorphin peptides, which are the natural
endogenous opioid ligands of the kappa-opioid receptors,
serve to modulate dopaminergic tone and countermod-
ulate cocaine-induced dopaminergic surges.In a recent
study, we examined the effects of steady-dose versus
escalating-dose binge-pattern cocaine administration
upon striatal preprodynorphin messenger ribonucleic
acid (mRNA) levels,and also on behavioral stereotypy.
22
We found that both steady-dose and escalating-dose
binge cocaine administration resulted in increased pre-
prodynorphin mRNA levels in the caudate-putamen,but
not in the nucleus accumbens.These are similar to all our
earlier studies of the impact of acute, subacute, and
chronic cocaine administrations.In this study,there were
no significant differences in preprodynorphin mRNA
levels when escalating doses (up to 30 mg/kg x 3, or a
total of 90 mg/day) were administered during the last five
days of 14-day chronic dosing,compared with a total of
45 mg/day,the steady dose “binge pattern.”
22These data
showed that the enhancement of gene expression of
dynorphin response to cocaine has probably reached its
maximum level at a dose of 45 mg/kg/day of cocaine,and
may or may not be dose-dependent at lower doses.
Further, in this study it was found that cocaine signifi-
cantly affected body weight in both paradigms,and that
both resulted in expression of behavioral stereotypy.
However,of note,one component of stereotypy,that is,
intense rapid head movements, was found to be both
dose- and time-dependent,with more profound effects
in the escalating-dose model.
22
Extending our much earlier studies in the rat,the effects
of the natural kappa-opioid receptor agonist,dynorphin
A(1-17),on both basal striatal dopamine levels and on
cocaine-induced increases in striatal dopamine levels,as
well as on cocaine-induced conditioned place preference,
was studied in C57BL/6J mice.
23 In earlier studies con-
ducted in the rat,we had shown that dynorphin applied
directly into the striatum causes a dose-dependent reduc-
tion in dopaminergic levels.In this recent study,dynor-
phin, at four different doses, was infused into the cau-
date-putamen,and dopamine levels were quantitatively
measured,using high-performance liquid chromatogra-
phy, in the extracellular fluid obtained during in vivo
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POMC proopiomelanocortinmicrodialysis in that brain region.
23Also,the effect of a
relatively high dose of dynorphin A on increases in
dopamine levels caused by 15 mg/kg of cocaine was mea-
sured using in vivo microdialysis.In related studies,the
effect of this dose of dynorphin A on cocaine-induced
conditioned place preference was studied.
23 We found
that dynorphin significantly decreased basal dopamine
levels in a dose-dependent manner and by more than
60% at the highest dose.Further,this effect was blocked
by preinjection with a selective kappa-opioid receptor
antagonist,nor-binaltorphimine (nor-BNI).
23 Further,it
was found that the highest dose of dynorphin studied (4.4
nanomolar) resulted in a complete block of the cocaine-
induced increases in dopamine levels,and also attenuated
locomotor activity induced by 15 mg/kg of cocaine,and
blocked the formation of cocaine-induced conditioned
place preference.
23These findings suggest that a dynor-
phin agonist might be helpful in managing cocaine and
other stimulant dependency by preventing cocaine or
other stimulant-induced dopamine surges.However,on
the other hand, any significant lowering of basal
dopaminergic tone could lead to dysphoria, and thus
more craving for a drug of abuse such as cocaine.
Therefore, it has made our laboratory suggest that a
potentially effective kappa-opioid receptor-directed com-
pound for management of cocaine addiction would prob-
ably be a kappa partial agonist,that is,with modest ago-
nist activity, but also antagonist activity, which should
render stable basal dopaminergic tones,yet significantly
attenuate cocaine- or other stimulant-induced dopamine
surges,as well as “liking of”cocaine.
In related studies,Zhang et al studied a related potent
synthetic kappa-agonist, R-84760, on cocaine-induced
increases in striatal dopamine levels in cocaine-induced
conditioned place preference in C57BL/6J mice.
24 R-
84760 is a novel nonpeptidic potent synthetic selective
kappa-opioid receptor agonist that has been studied to a
limited extent in humans for other indications. It was
found that,similarly to dynorphin itself,this compound
would effect a dose-dependent reduction in dopaminer-
gic tone,as measured during in vivo microdialysis in the
striatum.
24Also,it was shown that,like dynorphin,a low
dose (0.1 mg/kg) of R-84760 would block cocaine-
induced increases in the dopamine levels.Also, it was
found that similarly low doses of R-84760 would com-
pletely prevent the development of cocaine-induced con-
ditioned place preference and would attenuate locomo-
tor activity in the conditioning chamber.
24 Further,it was
documented that these effects of R-84760 on lowering
dopaminergic tone and cocaine-induced surges were
completely blocked by a selective kappa-antagonist,nor-
BNI.
23Thus,these effects were documented to be medi-
ated exclusively by the kappa-opioid receptor.
In different studies, we further explored the impact of
extended-access (10 hours) versus short-access (3 hours)
and also high- versus low-dose cocaine impact on self-
administration,cocaine-induced reinstatement,and on
brain mRNA levels.
25 It was again found that the escala-
tion of cocaine self-administration under long-access con-
ditions was greater than under short-access, and was
dose-dependent. Further, we showed that such long-
access,with animals who were allowed self-administra-
tion for 10 hours at high doses,resulted in an increased
susceptibility to drug-induced relapse.
25There were also
differences in neurobiological indices,specifically levels
of gene expression in those animals who were allowed to
have long access and high doses, compared with short
access.There were significant increases in proenkephalin
gene expression in the caudate-putamen following long-
access and high-dose self-administration.
25 Further,it was
found that dopamine D2 receptor mRNA levels in the
caudate-putamen and nucleus accumbens were signifi-
cantly correlated with cocaine reinstatement.
25 However,
there was no significant correlation between neuropep-
tide mRNA levels and cocaine-induced reinstatement.
25
Body weight progressively declined in the long-access
self-administering rats.
25 In parallel to these findings,food
consumption was also significantly reduced in each group
during self-administration, but the reduction in food
intake was much greater in the long-access rats.
25 During
the 10-day extinction period,food consumption was sig-
nificantly greater in the long-access,high-dose rats com-
pared with both the short-access and the low-dose rats,
and,in fact,food consumption during extinction in the
high-dose group was significantly greater than pre-self-
administration baseline levels.
25These findings are simi-
lar to observations made by our group in human cocaine
addicts in a controlled research setting.They have neg-
ative implications for some groups of people,where the
desire for thinness, or the desire for attaining the self-
image of thinness,may contribute to continued cocaine
(or other stimulant) self-administration.The many find-
ings from these long-access, high-dose cocaine self-
administration rodent studies,both our more recent ones,
as well as our earlier ones, along with the studies from
other groups,particularly those of Koob and of Miczek,
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tially for the human situation,but provide new insights
for further study both in laboratory-based and human
research paradigms.
5,7,25
We have conducted studies in collaboration with the
Laboratory of Dr Paul Greengard in which we have stud-
ied the impact of change of a single amino acid in an
important signal transduction protein on (i) both
dopaminergic responses to binge-pattern cocaine;as well
as (ii) acquisition;and then (iii) persistence and amounts
of self-administration of cocaine.
26 These studies were
conducted in four separate lines of mutant mice, each
with a mutation code for alanine introduced into the
gene for the protein DARPP-32 at four sites of phos-
phorylation.
26The four sites of phosphorylation chosen
were:(i) the protein kinase A site,threonine 34A;(ii) the
cyclin-dependent kinase-3 site,threonine 75A;(iii) the
kinase CK2 site,serine 97A;and finally,(iv) the kinase
CK1 site,serine 130A.In each case,animals were bred so
that both the mutant strain,as compared with the wild-
type strain,could be studied,with the single amino acid
change introduced into one of these four sites of critical
phosphorylation involved in different pathways of the
dopamine D1 receptor signal transduction through the
DARPP-32 cascade pathway.
26Acquisition of self-admin-
istration required significantly more time in the threo-
nine 34A-/- mice.However,once self-administration was
established, both threonine 34A and the serine 130A
DARPP-32 mutant mice administered significantly more
cocaine than did their wild-type controls.
26This became
especially apparent after training each of these strains on
a high dose of cocaine (1 mg/kg) and then starting the
self-administration studies for each strain using an even
higher dose of cocaine per injection (2 mg/kg),but then
progressing downward in concentration to 1.0,.05,and
.01 mg/kg per injection.As the dose was reduced below
1.0 mg/kg per injection,both the threonine 34A and the
serine 130A mice significantly increased lever pressing
to obtain more cocaine than did their matched wild-type
controls.
26 Such an increase during reduction of cocaine
concentration was not seen in either the threonine 75A
or the serine 97A mice.
26 This suggests that although
somewhat slower to acquire self-administration,both the
threonine 34 site and the serine 130 site of DARPP-32
phosphorylation are important for the persistence of,and
though not studied,possibly also to relapse to,cocaine
self-administration.Further,and in support of these find-
ings,studies using microdialysis in the freely-moving mice
could be carried out in three of the four strains (the
fourth strain was not available in adequate numbers for
study.) When this was performed,it was found that the
same two strains that administered more cocaine,that is,
the threonine 34A and the serine 130A,experienced a
much lower rise in extracellular fluid dopamine after
each of three binge cocaine injections than did the con-
trol mixed wild-type animals.
26 Further,this did not hap-
pen in the threonine 75A; these animals had a much
higher level of dopamine achieved after each dose of
binge cocaine, and these were animals that showed no
difference between the single amino acid change mutant
strain and the wild-type strain.These findings suggest
that a single amino acid change of a critical phosphory-
lation site may alter the behaviors of self-administration;
they also give further support to the concepts of many
groups,that a lower dopaminergic tone either at rest,or
achieved after any normal (for instance, a liked or
desired food) or abnormal (for instance, cocaine) self-
administration, may result in a lesser increase in
dopamine tone.Thus,such animals (or possibly people)
could be expected to seek more activation of this plea-
sure-related dopaminergic system, and thus have a
greater vulnerability to developing an addiction.
We have conducted studies in which morphine was self-
administered by animals and was available 18 hours/ses-
sion/day.
27 In these studies,animals were allowed to select
a more concentrated or less concentrated morphine solu-
tion and once stable choice was established,the concen-
trations were increased. The animals allowed such a
choice both escalated their morphine use to a much
greater extent than did steady-dose animals. After 14
days the animals were self-administering extremely large
amounts of morphine in the extended-access and esca-
lating high-dose model.
27These studies showed that the
average daily morphine self-administration increased
from 22.5 mg on day 1 up to 66.4 mg by day 14.
27
In addition to our neurobiological studies of drug addic-
tion by more traditional methods,such as gene expres-
sion, we have been collaborating with Dr Virginia
Pickel’s laboratory in the use of immunogold electron
microscopy (EM) to study drug-induced receptor traf-
ficking. In these studies we have been exploring the
effects of chronic intermittent self-administration of esca-
lating doses of morphine on ionotropic glutamate recep-
tor subunit trafficking in postsynaptic (ie,dendritic) sites
in neurons,a process that is emerging as a critical cellu-
lar substrate of neural plasticity.Because immunogold
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organelles,as well as presumably functional areas of the
plasma membrane,this approach provides a more func-
tional view than many of the more conventional meth-
ods of measuring receptor levels.We have been using
immunogold EM to study glutamate receptor localiza-
tion in neurons in portions of limbic-autonomic brain
areas,namely the reciprocally connected nucleus tractus
solitarius (NTS) and central (CeA) and basolateral
(BLA) nuclei of the amygdala,a brain circuit that may
play a critical role in homeostatic adaptations associated
with repetitive drug use.
28-29We have reported that the N-
methyl-D-aspartate (NMDA)-NR1 receptor subunit is
decreased on the dendritic plasma membrane of NTS
neurons in animals self-administering morphine, com-
pared with control animals not exposed to morphine.
28
Further,morphine self-administering rats showed region-
dependent changes in the subcellular location of the
AMPA-GluR1 receptor subunit in the amygdala.
Specifically, there was an increase in AMPA-GluR1
labeling on the dendritic plasma membrane of BLA neu-
rons and a concomitant decrease in dendritic AMPA-
GluR1 in CeA neurons from animals self-administering
morphine compared with control animals.
29These find-
ings suggest that chronic opiate self-administration is
associated with a redistribution of postsynaptic plasma
membrane glutamate receptor subunits that play an
important role in neural plasticity in brain circuitry reg-
ulating homeostatic processes.These adaptations may be
an important neural substrate for alterations in drug
reward,autonomic function,and behavioral processes,
each of which may be associated with the acquisition and
persistence of an addiction.
28,29
In four separate earlier studies from our laboratory we
have shown that chronic (14 days) binge-pattern cocaine
administration increases mu-opioid receptor mRNA lev-
els and also increases density of mu-opioid receptors in
specific brain regions where there are abundant
dopaminergic terminals from neurons located in the ven-
tral tegmental area.
30-33 In recent studies,Bailey and our
group have shown that early withdrawal from chronic
binge cocaine administration results in a recurrence of an
increase in mu-opioid receptor mRNA levels in the rat
frontal cortex,but only in this region.
34 In further studies,
Bailey found that there is a persistent upregulation of
mu-opioid receptors following long-term withdrawal
from escalating-dose binge-pattern cocaine.
35 In these
studies,animals were treated with our new modified par-
adigm of escalating-dose binge cocaine over 14 days,
which also results in an increase of mu-opioid receptor
density,but with no increase in endogenous endorphin
levels.
35 Following 14 days of withdrawal,there was still a
highly significant increase in mu-opioid receptor density,
and primarily in specific brain regions,again where there
are dopaminergic terminals from the ventral tegmental
area neurons and in fields in close proximity to both mu-
opioid receptor mRNA levels in the neurons producing
mu-opioid receptors and presenting them on the cell sur-
face.
35
In a further set of studies,Bailey explored changes in the
kappa-opioid receptors following 14-day withdrawal
from escalating-dose binge-pattern cocaine.
36 Here,very
different findings were made.Whereas in multiple stud-
ies from our laboratory we have found both increases in
gene expression of dynorphin,and increases in kappa-
opioid receptor densities, and a correlated increase in
kappa-opioid receptor mRNA levels,with kappa,unlike
mu-opioid receptors,which are found to be persistently
increased in density following 14 days of withdrawal from
binge-pattern escalating-dose cocaine,in this study there
was lowering of kappa-opioid receptors in two specific
brain regions in animals in long-term withdrawal from
cocaine.These areas included the basolateral amygdala
and septum.Such a decrease in density was not found in
other regions,but also with no persistence of increase in
density. These selective brain regions of decrease in
kappa-opioid receptor might contribute,in part,to the
biological substrate for the development of dysphoria,
which is usually observed in drug-free former cocaine-
dependent individuals.
36
Role of stress responsivity in the acquisition
and persistence of specific addictive diseases,
and the impact of chronic exposure to drugs
of abuse and withdrawal therefrom on 
components of the stress-responsive system,
along with identification of potential new tar-
gets for therapeutic intervention
In our recent studies,we have also further explored the rel-
ative role of dopamine D1 and dopamine D2 receptors in
various specific neurobiological changes,or neural plas-
ticity,resulting from chronic exposure to cocaine.Since it
has been well established that dopamine plays a major role
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been established for a long time that one of cocaine’s pri-
mary sites of action is the presynaptic reuptake transporter
for dopamine,where cocaine,by blocking reuptake,effects
a flooding of perisynaptic space with dopamine,we have
tried to dissect out the relative role of dopamine D1-like
versus dopamine D2-like receptors in some of the resul-
tant changes,both in behaviors,but also in gene expression
and neuropeptide levels.During the last 5 years,we have
completed further studies of the effects of selective
dopamine D1-like and also dopamine D2-like receptor
antagonists during acute binge-pattern cocaine adminis-
tration on corticotropin-releasing factor (CRF) mRNA
levels and pro-opiomelanocortin (POMC) mRNA levels
in the hypothalamus.In earlier studies,we have found that
both dopamine D1-like and also dopamine D2-like antag-
onists attenuate the chronic binge-pattern cocaine-induced
increase in adrenocorticotropin hormone (ACTH) and
corticosterone levels.
37 Further, we have shown that an
attenuation of cocaine-induced changes in stress hormone
levels similarly occurs in animals with complete deletion
of the DARPP-32 protein, which is involved directly in
dopamine D1 receptor signal transduction.
38 In our recent
studies,we again found that both dopamine D1-like and
dopamine D2-like antagonists attenuated the elevation of
corticosterone levels by acute,as well as in our earlier stud-
ies of chronic,binge-pattern cocaine.
39The previously iden-
tified acute binge cocaine-induced increases in hypothal-
amic CRF mRNA levels were not found in rats pretreated
either with a dopamine D1-like or D2-like antagonist.
Further,we found that neither the dopamine D1-like or
dopamine D2-like receptor antagonists alone, in the
absence of cocaine,altered mRNA levels of CRF in the
hypothalamus.Thus,these results further support our ear-
lier concept, that both dopamine D1 receptors and
dopamine D2 receptors mediate acute as well as chronic
cocaine’s stimulatory effects on the  hypothalamic-pitu-
itary-adrenal (HPA) axis.
39
Since neurobiological evidence has suggested that there
are functional interactions between the dopaminergic and
opioid systems regulating preproenkephalin and prepro-
dynorphin expression in the striatum,and since there is
increasing evidence there may be direct connections
between the dopaminergic system in the striatum and the
stress-responsive components of the hypothalamus, we
also raised the question of whether dopamine D1-like or
dopamine D2-like antagonists could play a role in regula-
tion of POMC mRNA levels in the hypothalamus.
39 In this
part of these studies,it was found that dopamine D2-like
receptor blockade increased the POMC mRNA levels in
the hypothalamus, a site with a different function than
POMC mRNA levels in the anterior pituitary.
39These find-
ings suggest that activation of the dopamine D2 receptor
may play a tonic inhibitory tone on hypothalamic POMC
gene expression.However,neither dopamine D2 block-
ade nor acute binge cocaine altered POMC mRNA levels
in the amygdala,the anterior pituitary,or the neurointer-
mediate level of the pituitary.Also,dopamine D1 receptor
blockade had no impact on hypothalamic POMC expres-
sion.Thus, these results both suggest a possible specific
role for dopamine D2 in at least acute cocaine effects on
hypothalamic POMC gene expression.
39
To further our studies on the relative role of the D1-like
and D2-like (and also D3-like, which are D2-like)
dopamine receptors in the setting of drug abuse, and,
specifically the impact of binge-pattern cocaine adminis-
tration,we have conducted studies using D1-/- or D3-/-
selective dopamine receptor gene deletion mice.
40 In
these studies, we examined mu-opioid receptor gene
expression in response to binge-pattern cocaine. We
found that,at basal state,there was a significant increase
in mu-opioid receptor mRNA levels in the frontal cortex
of both the D1-/- and D3-/- dopamine receptor gene
deletion mice,as compared with each of their wild-type
controls.
40 However,there were no differences in basal
levels of mu-opioid gene expression in the nucleus
accumbens or in the caudate-putamen in these gene dele-
tion mice.Strikingly,and in an opposite direction from
some of our earlier findings in wild-type rat models,acute
binge cocaine 15 mg/kg x 3 doses resulted in the restora-
tion of frontal cortex mu-opioid receptor mRNA levels
in the gene deletion mice to the levels of those in wild-
type mice.
40 Further,in the nucleus accumbens core,after
acute binge cocaine,there was an actual decrease in mu-
opioid receptor levels in the D1-/- mutant mice,whereas
in that brain region there was an increase in mu-opioid
receptor gene expression in D3-/- mice.
40 The opposite
pertained in the caudate-putamen, with an increase in
mu-opioid receptor levels after binge cocaine in the cau-
date-putamen of the D1-/- mice and a decrease in the
dopamine D3-/- mice.
40 In addition,a decrease in basal
orexin mRNA levels was found in the lateral hypothala-
mus of the D3-/- mice, which did not change with
cocaine.
40These findings suggested that both D1 and D3
receptors are involved in mu-opioid receptor gene regu-
lation in the frontal cortex, and also that D1 and D3
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cocaine on mu-opioid receptor gene expression in two
striatal areas, the caudate-putamen and the nucleus
accumbens core.In the control wild-type mice for the D1
receptor gene deletion, binge-pattern cocaine, as
expected,increased mu-opioid receptor gene expression.
However,in the wild-type controls for the dopamine D3
receptor knockout mice,there was a very modest,but not
significant,increase in mu-opioid gene expression after
binge cocaine, which was unexpected.
40 These findings
were made both in the caudate-putamen and in the
nucleus accumbens core, suggesting that in the actual
breeding of the wild-type animals,the controls for the D3
knockout groups may have been substantially different
from the wild-type mice which were the controls to the
D1 knockout mice.Of particular note was the finding of
increased basal levels of mu-opioid gene expression in
both the D1 and D3 knockout mice,though only in the
frontal cortex.These curious findings need to be studied
further in D1 and D3 gene deletion mice,and also in dif-
ferent strains of wild-type mice.
40
Most of the other studies of the impact of drug-induced
stress on many different parameters,with emphasis on
documentations of specific changes or evidence of neu-
roplasticity,have been conducted in rat models.In one
sequence of studies, we examined the effects of acute
morphine administration;chronic intermittent escalat-
ing-dose morphine (from 7.5 mg/kg/day on day 1 up to
120 mg/kg/day on day 10); and spontaneous 12-hour
withdrawal from chronic morphine administration,using
the escalating dose 10-day paradigm.
41 There were no
changes in mu-opioid receptor mRNA levels in the lat-
eral hypothalamus,the nucleus accumbens core,the cau-
date-putamen, or the amygdala following acute single
injection of morphine,nor after chronic 10-day intermit-
tent escalating-dose morphine.
41 However,after 12 hours
of withdrawal from 10-day chronic morphine adminis-
tration,several indices documenting stress response in
the HPA axis were found, including increased POMC
mRNA levels in the anterior pituitary, coupled with
increases in ACTH levels,and also increased mu-opioid
receptor mRNA levels in the lateral hypothalamus,the
nucleus accumbens core,and the caudate-putamen.The
changes in mu-opioid receptor gene expression suggest
both a rebound from the abrupt withdrawal from large
doses of the exogenous opioid morphine, as well as
changes integral to the HPA stress-responsive axis, as
well as in the hypothalamus.
41
Several studies from other laboratories have demon-
strated a role of lateral hypothalamic orexin (hypocre-
tin) activation in drug-related positive reward,as well as
in withdrawal effects;therefore gene expression of this
peptide was also studied.It has been established by oth-
ers that around half of the lateral hypothalamic orexin
neurons concomitantly express mu-opioid receptors.In
parallel to the increase in mu-opioid receptor gene
expression found in the lateral hypothalamus in acute
morphine withdrawal, similarly the levels of orexin
mRNA in the lateral hypothalamus were also found to
be increased.
41 No changes were found in the lateral
hypothalamic levels of preprodynorphin mRNA,a gene
which is known to be usually coexpressed with orexin in
that hypothalamic region. These findings suggest that
many different responses to the stress of morphine with-
drawal occur,or,alternatively,changes which occur in the
setting of withdrawal may drive the HPA axis activation
and stress of withdrawal,just as we have found to be the
case in our clinical studies.
42,43 Further,they suggest that
in the lateral hypothalamus activation of orexin gene
expression occurs in parallel to mu-opioid receptor gene
expression.These findings suggest a novel target for man-
aging opiate withdrawal.
41
In a subsequent series of studies,a similar but somewhat
different opioid administration paradigm was used. In
these studies,heroin,the most common human opiate of
abuse, was used,
44 coupled with a chronic, intermittent
escalating-dose administration paradigm and conducted
with doses of heroin ranging on day 1 from 7.5 mg/kg up
to 60 mg/kg by day 10 (it should be noted that in this
intermittent morphine escalating-dose paradigm, the
starting dose was the same for heroin and morphine (7.5
mg/kg), but after 10 days, the escalation was up to 120
mg/kg when morphine was used, and 60 mg/kg when
heroin was used.
44 One group of animals was then stud-
ied at the end of chronic escalating heroin administra-
tion; other animals were studied during early 12-hour
withdrawal from such chronic heroin exposure; and a
third group was studied after late 10 days of withdrawal
from chronic heroin exposure.
44 In this study,it was found
that arginine vasopressin mRNA levels were significantly
increased during early spontaneous withdrawal,and,of
several brain regions examined,only in the amygdala.
44
Further, separate studies showed that arginine vaso-
pressin mRNA levels were increased not only in early
spontaneous withdrawal from heroin in the amygdala,
but also following foot-shock in rats withdrawn from
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44 Such findings were not made
in the self-administration control,heroin-naïve rats.This
increase in arginine vasopressin mRNA levels was no
longer observed following 10 days of withdrawal from
chronic heroin.As in earlier studies,POMC mRNA lev-
els in the anterior pituitary were found to be increased,
both 30 min after chronic heroin administration,which
probably is a sign of very early withdrawal,as well as at
12 hours of withdrawal from heroin.POMC mRNA lev-
els had returned to normal after 10 days of withdrawal.
Similarly, ACTH levels were increased in early with-
drawal,coupled with a significant increase in plasma cor-
ticosterone,after 12 hours of withdrawal.Although the
levels of both ACTH and corticosterone at the end of the
chronic heroin administration,and thus 30 min,after the
last dose,were somewhat greater than those in the saline-
treated controls,these changes were not significant.
44
In much earlier basic clinical research studies,performed
in a stress-minimized research unit, documented that
plasma levels of ACTH and cortisol became elevated
before any signs and symptoms of opioid abstinence
were observed or reported following very-low-dose opi-
oid antagonist administration in opioid-dependent per-
sons,suggesting that HPA axis activation drives,in part,
the stress of opioid withdrawal,rather than reflecting a
response to that stress.
42,43
In separate,but related,studies,a model of heroin self-
administration was used.The dose of heroin administra-
tion was 0.05 mg/kg per infusion,and 7 daily short-access
(3-hour) sessions were used.
44 Since vasopressin mRNA
elevations had been observed in animal models of heroin
withdrawal, these studies were designed to look at the
effects of a vasopressin receptor (V1B receptor) antago-
nist, SSR149415, in that setting.Administration of this
compound was before the first extinction,or drug with-
drawal, session. The vasopressin receptor antagonist
dose-dependently attenuated foot-shock-induced rein-
statement and blocked heroin-induced reinstatement.
44
This antagonist also blunted HPA axis activation by foot-
shock.
44All these data suggest that arginine vasopressin
activation may occur during withdrawal from opiates,and
suggest that this peptide also may contribute to relapse
or reinstatement.Further,it is shown that,in the stress of
withdrawal,when foot-shock is added,there is a signifi-
cant increase in gene expression,and thus probably in the
arginine vasopressin peptide.Most important,the data
suggest that a vasopressin antagonist might attenuate
either stress (in these experiments,withdrawal-induced
and foot-shock-induced), and also drug-induced rein-
statement and relapse to opiate self-administration or
use. Further studies in rodent models are needed.The
arginine vasopressin receptor may become a novel tar-
get for therapeutics.
44
In other separate studies,possible alterations of arginine
vasopressin mRNA levels in the amygdala were studied
in animals undergoing acute withdrawal from cocaine.
45
In these studies,our model of steady-dose binge-pattern
(15 mg/kg every hour x 3 hours with no cocaine for 22
hours) administration for 14 days was used,followed by
acute withdrawal (3 hours), subacute withdrawal (24
hours), and long-term withdrawal (10 days).
45 It was
found that,although there were no changes in arginine
vasopressin mRNA levels in the amygdala immediately
following 14 days of cocaine administration,there were
increases in arginine vasopressin mRNA levels in acute
withdrawal (3 hours) from cocaine.Further,it was found
that the selective opioid receptor antagonist naloxone
blocked this increase.
45As found in previously reported
studies from our laboratory, chronic cocaine did not
result in increased mu-opioid mRNA levels in the amyg-
dala, nor did acute withdrawal from cocaine in these
studies.At 24 hours of withdrawal,significant increases
in arginine vasopressin mRNA levels in the amygdala
were still observed.However,these levels had returned
to normal after 10 days of withdrawal.
45As found in our
previous studies,adaptation or tolerance to the cocaine
effects on the HPA axis activation also was observed dur-
ing chronic binge cocaine.
45 However there were still
modestly elevated levels of ACTH during acute with-
drawal.As expected,naloxone produced modest eleva-
tions in ACTH levels in cocaine-naïve rats;naloxone did
not have such an effect in the acute or subacute cocaine-
withdrawn animals.There were no changes in arginine
vasopressin, or POMC, or mu-opioid receptor mRNA
levels in the hypothalamus following chronic cocaine
administration, and acute withdrawal from cocaine.
45
These findings suggested that opioid receptors may medi-
ate the increase in arginine vasopressin in the amygdala
during acute cocaine withdrawal,and suggest a potential
role for arginine vasopressin in the amygdala in some of
the adversive effects of withdrawal from cocaine as well
as in withdrawal from opiates.
45
A recent set of laboratory-based studies in rats affirm,and
further suggest a mechanism,for observations which we
have made in two separate clinical studies,around 7 years
apart, and in two parts of the world.
46-48 We have deter-
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370mined that steady-state methadone may attenuate or
eliminate the liking of cocaine,and may do so by a mu-
opioid receptor-mediated mechanism
49,50 In several earlier
studies,as discussed above,we have shown that chronic
binge-pattern cocaine administration results in an
increase in mu-opioid receptor density in multiple,but not
all,brain regions,and specifically in regions where there
are abundant dopaminergic terminals from dopamine
neurons in the ventral tegmental area and substantia
nigra compecta.
31-33 Further,we have shown that acute and
subacute,but not chronic,cocaine administration results
in an increase in mu-opioid receptor mRNA levels.
30 In
these recent studies,different paradigms were used.
41 In
one set of studies,rats were implanted with either saline-
or methadone-filled osmotic minipumps and then condi-
tioned with 1, 5, or 20 mg/kg cocaine intraperitoneally.
Animals with the 20 mg/kg/day or 55 mg/kg/day
methadone-filled osmotic pumps did not express cocaine-
induced place preference.
46 However,methadone pumps
at two doses (30 and 55 mg/kg/day) did not alter intra-
venous self-administration of cocaine using a continuous
schedule of reinforcement with different doses of cocaine
(0.1, 0.5, and 2.0 mg/kg/infusion) studied. Mu-opioid
receptor mRNA levels were measured in animals treated
with cocaine as part of conditioning for place preference.
As in earlier studies, it was shown that this subacute
cocaine administration resulted in increased mu-opioid
receptor mRNA levels in the nucleus accumbens core and
in the frontal cortex 10 days after cocaine conditioning.
46
However,this increase in mu-opioid receptor mRNA lev-
els was attenuated or eliminated by the steady-dose infu-
sion of methadone.Earlier studies have shown that the
dose of 55 mg/kg/day subcutaneously by pump in the rat
results in a plasma level similar to that in patients seen in
methadone maintenance.
49 These studies showed that,
although high doses of methadone delivered by pump did
not alter the direct reinforcing effects of cocaine as seen
in self-administration, those doses of methadone did
block both spontaneous and cocaine-induced “seeking”
or “liking”10 days after cocaine conditioning.Further,we
have suggested that this may be through the mechanism
of methadone attenuating or preventing the relative
endorphin deficiency resulting from the increased mu-
opioid receptor density preceded by increased mu-opioid
receptor gene expression, but with no concomitant
increase in the endogenous opioids that bind to the mu
receptor,that is,no increase in beta-endorphin or in the
enkephalin peptides.
46
These studies also build upon the early and also much
more recent findings that,despite the fact that up to 70%
of all persons in the middle Atlantic states,as well as cur-
rently in Tel Aviv,Israel,have concomitant dependence
upon cocaine,when presenting for treatment for long-
standing dependence on heroin,after 1 year or more of
methadone treatment, as expected, the numbers using
heroin dropped precipitously, to less than 20% of
patients using heroin at any time (as contrasted to heroin
use by all patients 3 to 6 times a day prior to entry).This
was accompanied by the more surprising findings that
during steady-dose methadone maintenance treatment,
the percentage of persons dependent on cocaine drops
down to less than 20%,and those using any cocaine to
less than 30%.
47,48 Although these beneficial results of
methadone maintenance on managing cocaine addiction
were always attributed to the counseling and other psy-
chosocial benefits derived from a good methadone main-
tenance program,we have,over the last decade,hypoth-
esized that a pharmacological mechanism also is in place,
a hypothesis based on our findings that binge cocaine
increases acutely mu-opioid receptor gene expression
and on a chronic basis,mu-opioid receptor density,and
further,that a relative endorphin deficiency thus devel-
ops in humans,since there is no concomitant increase of
beta-endorphin or enkephalins,as may be directly docu-
mented by stress-responsive metyrapone testing.
50These
findings suggest that possibly an opioid agonist such as
methadone, or possibly a partial agonist, such as
buprenorphine,might be able to be effectively used to
treat very severe,long-term,cocaine-dependent persons
who have not responded to any other available current
treatment.Since there are no effective targeted pharma-
cotherapies for cocaine addiction,the potential target of
the mu-opioid receptor,with now a neurobiological basis
for such treatment,might be warranted.
In other studies,conducted by a collaboration with our
colleagues at the Karolinska Institute in Stockholm,
Sweden, yet another potential target for future thera-
peutic use, a nociceptin/orphanin FQ receptor agonist
(Ro64-6198) was found to reduce alcohol self-adminis-
tration,and,further,and importantly,to prevent relapse
to alcohol drinking in a rat model.
51 Other orphanin-noci-
ceptin (ORL-1) receptor agonists may be found to have
effectiveness in treatment of alcoholism and possibly
other specific addictive diseases,which involve interac-
tions between the dopaminergic system and different
components of the opioid and opioid-like system.
51
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371Basic clinical research related to specific
addictive diseases, with emphasis on stress
responsivity: all research focused on 
treatment improvement
Corticotropin-releasing factor (CRF),synthesized and
released in the hypothalamus,passes through the portal
blood system to the anterior pituitary, where it effects
processing and release of the single gene product of the
POMC gene (reviewed in ref 7). This large peptide is
then further processed to yield many biologically active
and important neuropeptides,including the major stress-
responsive and glucocorticoid-regulated peptide,ACTH,
as well as the longest (31 amino acids) of the endogenous
opioids,and a primary ligand of the endogenous mu-opi-
oid receptor,beta-endorphin.ACTH and beta-endorphin
are released in equimolar amounts from the anterior
pituitary sites in humans (who, unlike rodents, do not
possess an intermediate lobe in the pituitary except tran-
siently during pregnancy.) ACTH and beta-endorphin
pass into the general circulation.ACTH impacts directly
upon the adrenal cortex to bring about the processing
and release of the major glucocorticoid in humans,corti-
sol,in addition to altering and enhancing the biotrans-
formation and release of several other steroid hormones.
Beta-endorphin may act at many peripheral sites.There
is some evidence that there may be retrograde passage
of these two neuropeptides back into the hypothalamic
region,which in human and nonhuman primates,but not
in rodents, lies partially outside the brain barrier.
Glucocorticoids have been documented for a very long
time to negatively regulate the HPA axis in a negative-
feedback mode, with cortisol being the primary gluco-
corticoid in humans, non-human primates and guinea
pigs,and corticosterone,the primary glucocorticoid hav-
ing this effect in rats and mice.Thus,cortisol acts at both
the hypothalamic sites of CRF production and at the
anterior pituitary sites of POMC processing and release,
to transiently attenuate or inhibit the release of these
hormones.A 24-hour circadian rhythm is thus achieved,
with the lowest levels of CRF,ACTH, beta-endorphin
and thus cortisol in the late afternoon and early evening
in humans,and with levels rising again in the early morn-
ing hours, the opposite times pertain in rodents, with
highest hormone levels at night,at the beginning of the
activity period.
Based on early findings of Volavka,our group and a few
others years ago began to study the possible role of the
endogenous opioid system,in particular,the mu-opioid
receptor system,in also modulating the HPA axis.In sev-
eral studies we have shown that the HPA axis is inhibited
by the mu-opioid receptor system (reviewed in refs
5,7,8). In one study from our group, we looked at high
and very high doses of two different selective mu-opioid
receptor antagonists,both of which can be administered
intravenously in humans, naloxone and nalmefene.
52
Studies using nonhuman primate membranes and,more
recently, studies using cloned human genes in proper
molecular-cellular constructs,have shown that,in contrast
to rodents,naloxone binds almost exclusively to the mu-
opioid receptor and acts as an antagonist.
52 Nalmefene,
on the other hand,binds to both mu- and kappa-opioid
receptors.Very recently,in collaboration with the group
of Bidlack,we have shown that the kappa opioid recep-
tor effect of nalmefene is that of a partial agonist (that is,
with some agonist and some antagonist properties),
whereas the mu component is pure mu-opioid receptor
antagonist.
53 Since we have studied both of these com-
pounds in several earlier clinical research studies, we
elected to use high and very high doses of each, to be
sure that the ceiling of the effective doses in humans was
exceeded.We found,as we and others had shown before,
that naloxone activates the HPA axis by disinhibition and
causes significant increases in both ACTH and cortisol.
Of great interest in this study,however,was the finding
that nalmefene causes a significantly greater activation
of the HPA axis,with higher resultant peripheral levels
of ACTH and cortisol.
46 Our more recent studies, in
which we found that the kappa component of nalmefene
is a partial agonist,suggest that whereas the mu antago-
nists act at mu-opioid receptors of the hypothalamic and
anterior pituitary sites, and through the mechanism of
disinhibition bring about the increased release of CRF
and ACTH and beta-endorphin,the kappa partial ago-
nist component of nalmefene may act directly to enhance
release of CRF and/or of the POMC peptides,ACTH
and beta-endorphin, thus directly activating the HPA
stress-responsive axis,which has been suggested by sev-
eral workers in preclinical studies.
52,53This possibility has
not,however,been well studied with any of the very few
selective kappa agonists which have ever been intro-
duced to human use,and only a few additional studies of
these kappa agonists or partial agonists have been con-
ducted in nonhuman primates.
In earlier studies,it has been shown that activation of the
HPA axis, with increased levels of plasma ACTH and
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372cortisol,occurs after administration of alcohol or cocaine,
and many groups have made similar findings in animal
models.Further,we have shown that tolerance develops
to this HPA activation effect of both cocaine and alcohol.
In other studies,we have suggested that activation of the
HPA axis is sought by the rat or mouse, and by the
human.In human studies conducted,in collaboration,by
O’Malley at Yale in a clinical research setting,naltrexone,
a selective mu-opioid antagonist with some kappa antag-
onist activity,was administered for 1 week to alcoholics
and compared with placebo administered for one week
to a similar group.
54Then a laboratory session was con-
ducted in which limited alcohol self-administration was
permitted for up to 2 hours. We found, just as in the
numerous field trials,that alcoholics receiving naltrexone
drank significantly fewer drinks.
54 Because of the nal-
trexone disinhibition of the hypothalamic-pituitary sites
of the HPA axis,there was a significant increase in levels
of ACTH and cortisol in alcoholics treated with naltrex-
one after consumption of fewer than two drinks,whereas
the much larger amounts of alcohol consumed by the
alcoholics receiving placebo resulted in no significant
activation of this axis.
54 Further,on responding to specific
questionnaires,the alcoholics receiving naltrexone,and
who had consumed only a small amount of alcohol,but
had experienced modest activation of the HPA axis,felt
no further “craving,”or desire to drink alcohol,and this
decrease in craving was correlated to the increase of
serum cortisol levels. The opposite pertained in those
alcoholics receiving a placebo,who had consumed more
alcohol, but had no activation of the HPA axis, and no
increase in cortisol, a significant urge to drink alcohol
persisted.
54
Many of our earlier studies have shown that short-acting
opiates,opposite from the effects of cocaine and alcohol
in the HPA axis, profoundly attenuate or suppress the
HPA axis,resulting in lowered levels of ACTH and cor-
tisol after opiate administration.However,after tolerance
and physical dependence have developed,in the setting
of withdrawal from opiates,profound activation of the
HPA axis occurs with increases in levels of ACTH and
cortisol. The neuroendocrine changes of opiate with-
drawal look very similar to the normal response to a spe-
cific mu opioid receptor antagonist,such as naltrexone,
when given to a healthy volunteer.Therefore,it is not sur-
prising,as we had predicted,that most opiate addicts will
not willingly accept chronic daily naltrexone or other opi-
oid antagonist treatment once experienced,whereas alco-
holics would accept such treatment,and might be directly
benefited. Giving an opioid antagonist to any opiate-
dependent person is contraindicated,because profound
activation of the stress-responsive axis will occur and cre-
ates a very adversive and noxious experience.In many of
our earlier studies, we have shown that during chronic
methadone maintenance treatment, which provides
steady perfusion with a synthetic ligand of the mu-opioid
receptor,complete normalization of the HPA axis occurs,
including normalization of basal levels of hormones,as
well as responsivity in various functional tests.
To dissect further the relative contribution of the gluco-
corticoid system contrasted to the mu-opioid receptor
endogenous ligands, that is, beta-endorphins and
enkephalins, we have conducted further studies using
metyrapone.In humans,metyrapone blocks the final step
of cortisol synthesis,that is,11-β-hydroxylation.In the sin-
gle oral dose test using metyrapone,the synthesis of corti-
sol is blocked for about 8 hours,and then returns to nor-
mal. Therefore, one can measure the levels of ACTH
(which also reflect the equimolar release and levels of
beta-endorphin) following metyrapone administration
which are elevated because with cortisol synthesis blocked,
and the normal negative feedback is transiently cut off.In
healthy human beings, with normal endogenous opioid
systems,the mu-opioid receptor system responds to bring
a check, or brake, to the increased release and levels of
ACTH (and beta-endorphin).However,we had shown in
several earlier studies that in medication-free,drug-free
former heroin addicts,there is no such mu-opioid recep-
tor-mediated brake, and thus hyper-responsivity to
metyrapone testing is observed (reviewed in refs 5,7).
Further,we had reported that in abstinent cocaine addicts
a similar hyper-responsivity to metyrapone testing exists.
50
This hyper-responsivity, therefore, suggests a relative
endorphin deficiency,which our laboratory-based studies
also support.
30-33,50As discussed above,we have found that
chronic binge cocaine administration causes an increase in
gene expression in the mu-opioid receptor,as well as an
increase in density in mu-opioid receptors,in specific brain
regions with abundant dopaminergic terminals,and,fur-
ther,in recent studies,we have found that this increase in
mu-opioid receptor density persists for a protracted period
of time after last cocaine exposure.
30-32,35 However,we have
also shown that there is no increase of the endogenous
opioids that bind at the mu receptor.Thus a relative endor-
phin deficiency develops (or possibly was present a pri-
ori on a genetic or environmentally-induced basis).
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sion tomography (PET) showed similarly the mu-opioid
receptor density being increased in recently-abstinent
cocaine addicts,and further more recently have shown
that this increase persists for protracted periods of time
into successful cocaine abstinence.
55,56 Thus, a relative
endorphin deficiency has been documented both in
humans as well as in rodent models,in humans directly
shown by testing of the stress-responsive system.In sev-
eral studies,we have found that metyrapone responsiv-
ity is abnormal in opiate addicts,but becomes normalized
in methadone maintenance patients (reviewed in refs
5,7).We also have shown that abnormal hyper-respon-
sivity occurs in cocaine addicts.
5,7 In a more recent study,
we again documented the normalization during
methadone maintenance treatment.
50We also conducted
studies in a subgroup of methadone maintenance
patients who continued during 6-month treatment or
more to meet the criteria of cocaine dependence.
50This
group was maintained on moderate doses of methadone
(60 to 90 mg/day).As discussed above,an early clinical
study from our laboratory, a very recent clinical study
from our laboratory,and a recent laboratory-based study
have all suggested that increasing the dose of methadone
may decrease cocaine addiction in maintenance patients
with dual-dependency,and further,in the rodent model,
that the addition of steady-state methadone may prevent
alterations in mu-opioid receptor gene expression and
attenuate or prevent conditioned place preference to
cocaine.
46-48
In another set of studies reported in the last decade we
have re-explored the glucocorticoid negative feedback
both in methadone-maintained former heroin addicts,as
well as those with ongoing cocaine dependence.
57 In all
our earlier studies,we found,surprisingly,that all of the
methadone-maintained patients had normal suppression
to dexamethasone and, in this study, we also used two
lower doses than the usual suppression dose,that is,0.5
and .125 mg and found that all subjects suppressed com-
pletely (as reviewed in refs 5,7,57). All the cocaine-
dependent methadone-maintained patients also sup-
pressed completely. Although not significant, the
glucocorticoid feedback effects in the cocaine-dependent,
methadone-maintained patients,and also in the other-
wise well-stabilized methadone-maintained patients
appeared to be greater than the normal volunteers in the
late afternoon,suggesting that there may be a modestly
altered,or enhanced,negative feedback by glucocorti-
coids,in at least some subjects.
57This,in turn,may con-
tribute to the observed attenuation of both basal and
cocaine-induced responsivity of the HPA axis in humans
and in rodents in other studies from our laboratory and
others.
In another study, we examined the effect of corti-
cotropin-releasing factor in methadone-maintained ver-
sus control subjects.In this study,we found differences
between long-term well-stabilized methadone-main-
tained subjects as compared with normal control sub-
jects.
58 In this study, two doses of CRF were used; one
lower than the usual dose (0.5 µg/kg) and one dose
higher (2.0 mg/kg) than usually used in the neuroen-
docrine diagnostic procedure (100 µg, irrespective of
weight).
58 There was no difference in hormonal mea-
surements between the two groups following placebo
administration,nor during low-dose hCRF administra-
tion.However,following high-dose CRF administration,
the methadone-maintained patients displayed a signifi-
cantly greater increase in plasma ACTH levels than did
the normal volunteers.
58This suggested that in long-term
methadone-maintained patients some abnormalities in
HPA axis responsivity may pertain,in this case,a greater
sensitivity of the anterior pituitary to CRF stimulation.
In turn, these findings suggest that the basal and peak
levels of CRF may be slightly reduced in stable
methadone maintenance patients,possibly related to the
increased sensitivity to negative feedback by glucoco-
corticoids,as discussed above,or due to the steady but
high and exogenous opioid tone in patients in treatment
with the long-acting mu agonists.
57,58 Further studies to
explore this altered sensitivity in other persons with spe-
cific addictive diseases, not in treatment, as well as in
treatment,are in progress.
In another series of studies,we have been able to pursue
in humans findings which we and others had made in
rodents,that is,that dynorphin,the natural endogenous
opioid ligand of the kappa-opioid receptor,may directly
act to alter (lower) dopaminergic tone.We have been
able to access dynorphin A(1-13),a natural-sequenced
dynorphin four residues shorter than the natural dynor-
phin A(1-17) for research use under an investigator-ini-
tiated investigational new drug application (IND)
approved by the US Food and Drug Administration.
Building upon the established biological fact that, in
humans, prolactin release is almost exclusively under
dopaminergic tone,and thus,that a lowering of dopamine
in the tuberoinfundibular dopaminergic region results in
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healthy volunteers using two different doses of intra-
venously-administered dynorphin A(1-13) (120 µg/kg
and 500 µg/kg).Since in humans some of the hypothala-
mus lies outside the blood-brain barrier,we assumed that
the peptide dynorphin would be able to act on this
tuberoinfundibular dopaminergic system.When we con-
ducted these studies in a stress-minimized environment
of our Rockefeller Hospital clinical research center,we
found that peripheral administration of dynorphin A(1-
13) gave a prompt dose-dependent increase in serum
prolactin levels, which then returned to normal within
120 minutes.
59This duration of action was much longer
than we predicted,based on our in vitro biotransforma-
tion studies in which we established the probable half-life
of dynorphin A(1-13) in human blood.
60 Of interest,with
respect to the possible effect of dynorphin on the HPA
axis,we found no increment in ACTH or CRF following
peripheral dynorphin administration.
59 To document
whether the dynorphin effect was modulated by the
endogenous opioid system,we conducted studies using
the lower dose of dynorphin A(1-13) following pretreat-
ment with either naloxone or nalmefene,both selective
mu-opioid receptor antagonists, and one (nalmefene)
with partial kappa-opioid agonist activity.
59We found pre-
treatment with either of these compounds attenuated the
rise in serum prolactin.
59 In these initial studies,a further
very provocative (but not completely unexpected given
the physiological differences) observation was made,an
unusual finding in our human studies of addictive dis-
eases, specifically that female subjects had modestly
higher basal levels of prolactin than males, but when
given dynorphin, gave a significantly exaggerated
response,with higher levels of prolactin achieved after
dynorphin administration and thus the reduction of
dopamine in the tuberoinfundibular region.
59 Thus, a
clear gender difference was observed.Our subsequent
studies of dynorphin effects now must be done always
considering males and females separately.
In a second set of studies,we have addressed the ques-
tion of whether or not the dynorphin responsivity,with
respect to lowering dopaminergic tone,will occur simi-
larly in healthy long-term well-stabilized methadone-
maintained subjects.
61Two doses of dynorphin again were
used for study in both a new group of healthy volunteer
subjects and in a group of long-term stable methadone-
maintained patients.
61 Again, in the healthy volunteer
subjects,a dose-dependent rise in serum prolactin was
observed after dynorphin administration.
61 Similarly,in
the methadone-maintained patients (receiving 80 to 120
mg/day of methadone), a dose-dependent rise in pro-
lactin occurs.
61 Because years ago (published in 1978 by
our group),we had shown that methadone itself,acting
as a mu opioid receptor agonist,acts to lower dopamin-
ergic tone, causes increase in serum prolactin, which
occurs at time of peak plasma levels of methadone (that
is,around 2 to 4 hours after oral methadone dose),in the
dynorphin studies,we withheld the methadone dose until
60 minutes after the dynorphin was given.
62 In these sub-
jects,as in our much earlier studies,we showed a second
and separate brisk rise in prolactin levels,beginning at
2 hours after methadone administration and remaining
elevated at 5 hours after methadone administration.
Again,in the methadone-maintained patients,as in both
groups of healthy volunteer subjects,there was a dose-
dependent dynorphin-induced rise in prolactin levels
which returned to basal levels by 90 to 120 minutes.Thus,
in this study, we were able to observe both the dynor-
phin- and methadone-induced lowering of tuberoin-
fundibular dopaminergic tone,resulting in both rises in
serum prolactin levels.
61,62
In yet another series of studies, we had observed that
when given to healthy volunteers nalmefene caused a
small but modest rise in serum prolactin levels.
53
Therefore,we entered into a collaboration with Bidlack,
and in that collaboration addressed directly the issue of
whether the kappa opioid receptor activity of nalmefene
is antagonist,or possibly,as we hypothesized,partial ago-
nist.It was found clearly that nalmefene possesses kappa-
opioid receptor partial agonist activity in in vitro studies
using appropriate molecular cellular constructs.
53 It was
reconfirmed that the mu opioid receptor action of nalme-
fene is only that of antagonism;the kappa opioid recep-
tor action is both agonism (partial agonist) and antago-
nism.
53 Further, we were able to show that nalmefene
effects a modest elevation of prolactin levels,suggesting
a modest lowering of dopaminergic tone.This suggests,
however, that nalmefene or other mu-opioid receptor
antagonists,which have kappa-partial agonism (proba-
bly also true for naltrexone) may have augmented bene-
fit for management of alcoholism,and possibly even for
treatment for stimulant, such as cocaine, dependency,
since a modest lowering of dopaminergic tone could be
helpful in decreasing or attenuating the “reward”effect,
whereas the inhibition of the mu-opioid receptor regu-
lation of the stress-responsive HPA axis could provide
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375modest activation of this axis,which we have directly doc-
umented to be sought by alcoholics, and in our animal
modeling suggests is also sought by the cocaine self-
administering animals.
19,54 In these basic clinical research
studies,we have again found an extremely important role
of the mu-opioid receptor system,as well as identifying
a previously not-appreciated role of the kappa-opioid
receptor system in modulation of the human stress-
responsive HPA axis.
Our genetics work,including our work in physiogenetics,
has not been discussed herein, but has been reviewed
elsewhere,as discussed above.
5,8-11
All these findings have taught us that physiogenetics may
occur,that is,difference in our response to our own pro-
teins,peptides,neurotransmitters,or steroids,based on a
polymorphism of a receptor or some polymorphism of
the ligand or the pathway producing the ligand.Further,
such studies,in the future,may give us increasing insights
into targets for therapeutics,as well as providing a basis
for effective primary prevention of specific addictive dis-
eases. ❏
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Opioides, dopamina, estrés y las adicciones
Los objetivos expresados por Dialogues in Clinical
Neuroscience son servir como interfase entre la
neuropsiquiatría clínica y las neurociencias al entre-
gar información actualizada y conocimientos origi-
nales de aspectos clínicos, biológicos y terapéuticos
relevantes. Mi laboratorio, el Laboratorio de la
Biología de las Enfermedades Adictivas de la
Rockefeller University, se ha orientado por años a
la “investigación translacional bidireccional”, es
decir, el aprendizaje mediante cuidadosas observa-
ciones y análisis de poblaciones de pacientes con la
enfermedad en estudio, en este caso, enfermeda-
des adictivas primariamente específicas, y luego uti-
lizar ese conocimiento para crear modelos anima-
les mejorados u otros paradigmas de investigación
basados en el laboratorio; y al mismo tiempo, tras-
ladar los resultados de estudios realizadas en el
mesón del laboratorio a la clínica tan pronto como
sea apropiado y posible. En esta revisión por invi-
tación, el foco de atención serán las perspectivas de
nuestro Laboratorio de la Biología de las
Enfermedades Adictivas, del Instituto Nacional de
Salud y del Centro de Investigación del Abuso de
Drogas del Instituto Nacional, incluyendo investi-
gación neurobiológica molecular basada en el labo-
ratorio, investigación con algunos modelos anima-
les diseñados para simular patrones humanos de
abuso y adicción a drogas, y también investigación
clínica básica entrelazada con investigación rela-
cionada con el tratamiento.      
Opioïdes, dopamine, stress et addictions
L’objectif des Dialogues in Clinical Neuroscience est
de servir « d’interface entre la neuropsychiatrie cli-
nique et les neurosciences en délivrant une infor-
mation à la pointe des connaissances et des points
de vue originaux sur des aspects cliniques, biolo-
giques et thérapeutiques pertinents ». Le labora-
toire de Biology of Addictive Diseases que je dirige
à l’université Rockefeller, se concentre depuis des
années sur «la recherche translationnelle bidirec-
tionnelle», composée de recueil d’informations par
l’observation soigneuse et l’étude de populations
de patients atteints de troubles donnés, dans le cas
de notre laboratoire plus spécifiquement de mala-
dies addictives, et de l’utilisation ultérieure de ces
connaissances pour créer un modèle animal amé-
lioré ou d’autres modèles de recherche en labora-
toire. Parallèlement, il s’agit d’exporter les résultats
de recherche obtenus in vitro aussi vite que cela est
opportun et faisable, vers la clinique. Dans cette
revue, nous avons donc mis l’accent sur les pers-
pectives du laboratoire de Biology of Addictive
Diseases and related National Institutes of
Health/National Institute on Drug Abuse research
Center ; elles incluent la recherche neurobiologique
moléculaire de laboratoire qui utilise différents
modèles animaux afin d’imiter les modèles humains
d’abus de drogues et d’addiction, aussi bien que la
recherche clinique de base, étroitement liée à la
recherche thérapeutique.Opioids,dopamine,stress,and the addictions - Kreek Dialogues in Clinical Neuroscience - Vol 9 . No.4 . 2007
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